Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DCTH vs BMRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–2 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: DCTH 6 – 0 BMRA Matrix Metrics: DCTH 7 – 2 BMRA

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.85 (N/M Forward P/E, 5.2% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).

  • Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (7–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -125.2% operating margin) and revenue trajectory (+70.7% vs. -8.3% YoY).
  • Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 65.0); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DCTH vs BMRA
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.85
-3.41% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.65β · 132% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 65
RSI-14: 65.0 · SMA20: $16.41 · SMA50: $15.95
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96

6-Pillar Scorecard Institutional Category Breakdown (DCTH 6 – 0 BMRA)

Columns: Metric · DCTH · BMRA
1. Valuation Multiples DCTH
Forward P/E N/M N/M
Trailing P/E 133.6x N/M
PEG Ratio 1.60x N/M
EV / Revenue 6.3x 1.1x
2. Growth & Scale DCTH
Revenue Growth (YoY) +70.7% -8.3%
Earnings Growth (YoY) +750.0% +0.0%
TTM Revenue (USD) $110M $4.3M
Market Cap $743.8M $6.0M
3. Profitability & Quality DCTH
Gross Margin 87.6% 0.9%
Operating Margin 5.2% -125.2%
Net Profit Margin 6.0% -115.5%
Return on Equity (ROE) 5.4% -113.8%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $20M -$3.2M
Cash Flow Margin 18.3% -73.5%
Net Cash / Leverage $53M Net Cash $1.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 109.3% (43rd %ile) N/A (N/A)
Put/Call OI Skew 0.11x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 82.4% of Rev ($91M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DCTH (7) vs BMRA (2)
Institutional Metric DCTH BMRA Criterion Row Edge
Market Capitalization
Scale
$743.8M $6.0M Larger Scale DCTH
Trailing P/E Ratio
Valuation
133.6x N/M Lower Multiple DCTH
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+70.7% -8.3% Higher Growth DCTH
Operating Margin (TTM)
Profitability
5.2% -125.2% Higher Margin DCTH
Net Profit Margin
Profitability
6.0% -115.5% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
5.4% -113.8% Higher ROE DCTH
52-Week Range Position
Momentum
82% ($8–$23) 4% ($1–$3) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
1.65β · 132% Vol 0.67β · 62% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 44.5 / 100 (HOLD) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$110M $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.6% 0.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.60x PEG · 6.3x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($53M Net Cash) -$3.2M ($1.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +69.17 pp
DCTH: +40.98% · BMRA: -28.19%
3M Horizon DCTH +34.7 pp
DCTH: +17.73% · BMRA: -16.97%
6M Horizon DCTH +119.95 pp
DCTH: +78.99% · BMRA: -40.96%
1Y Horizon DCTH +177.41 pp
DCTH: +130.55% · BMRA: -46.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DCTH Revenue BMRA Revenue DCTH Op. Margin BMRA Op. Margin Margin Leader
FY2019 N/A $10M N/A -46.4% BMRA
FY2020 N/A $10M N/A -41.0% BMRA
FY2021 $0M $10M -690.0% -104.2% BMRA
FY2022 $0M $20M -1245.1% -24.0% BMRA
FY2023 $0M $10M -1849.0% -135.3% BMRA
FY2024 $40M $10M -33.4% -117.6% DCTH
FY2025 $90M $10M 0.8% -96.7% DCTH
FY2026 N/A $0M N/A -119.5% BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DCTH vs BMRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.85 (N/M Forward P/E, 5.2% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (7–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -125.2% operating margin) and revenue trajectory (+70.7% vs. -8.3% YoY). Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 65.0); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), DCTH cumulative revenue shifted +125.0% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.

DCTH screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus BMRA (-113.8% ROE) capital efficiency.

In options market volatility and institutional positioning, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.65β · 132% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.